NorthWest Biotherapeutics Inc (NWBO)

[JRIII]

Even JRIII, whatever his issue is, has my empathy. Doesn’t mean I won’t go toe to toe with him under certain conditions.

You pick the course, doc. I'll give you three strokes. Although 18 holes of lectures about how your life experiences have shaped your superior world view might be a bit much, so let's keep it to nine. Also, I think the word you may have meant to use is "sympathy" not "empathy". Different words, different meanings. Empathy would require someone with your more advanced perspective to lower himself to my level, and that might be a bit of a challenge. Your sympathy for my pained condition, otoh, would be greatly appreciated.

I will say that I'm glad to see you and biosectinvestor are not falling for this ridiculous four-day rule nonsense. The fact that Joan Lappin has should tell you all you need to know about her credibility on the subject of NWBO. Her article was good for another price pump that allowed some friendly to cash out three million shares before the bad news hits. It's an amazingly brazen game they've been playing.

And while I know that you and biosectinvestor remain optimistic about what the company will eventually share regarding this now-14-year-old Phase 3 trial, I think you both have enough sense to know that if these results were truly a grand slam home run we would have learned about it a long time ago. I think you both recognize that there will be a lot of "greyness" with this data and much will depend on how well they spin it. Some things we know to be true:

- The CEO wrote a letter to the FDA begging them to consider alternative approvals for trials that fail to show efficacy on the primary indicator.
- At last year's ASM phone conference (almost impossible to believe that phone call was eight months ago), the CEO told us that regardless of efficacy outcome, she hopes this trial will serve as an important contribution to the field of cancer research.
- Literally at the last moment before releasing the data, the company appears to have changed the endpoints of the trial, but hasn't said anything about it to shareholders.
. . . and one other thing we know to be true:
- The people running this company are liars. They have repeatedly lied to shareholders, shared misinformation, and have built false expectations - over and over and over again.

I don't really care for people like that, and I'm not the kind of person who believes the end justifies the means. Nor do I believe the excuses that the lies and misinformation are not their fault. Normally I would not invest in a company run by these types of people, but I did not know enough about them when I bought in and when I did find out who they really are it was too late and I was trapped. More than the money, my greatest regret is wasting so much time on these people. I did sell a sizeable chunk a couple of weeks ago at $1.72, and I feel good about that. I will hold on to the rest because I think it will pop a good bit leading up to the release of information. And there's always a chance, however slim, that you and biosectinvestor are right and that they will successfully be able to turn lemons into lemonade. But, personally, I think the market is far too smart to be duped by whatever scheme they are working up. We shall see.